hendra
nipah
virus
relat
emerg
paramyxovirus
infect
caus
diseas
anim
human
diseas
manifest
gener
vascul
affect
multipl
organ
sever
respiratori
central
nervou
system
high
case
fatal
persontoperson
transmiss
associ
recent
niv
outbreak
recent
reemerg
hev
emphas
import
necess
effect
therapeut
novel
agent
recent
year
henipaviru
research
reveal
complet
understand
pathogenesi
consequ
viabl
approach
toward
vaccin
therapeut
emerg
strategi
target
earli
step
viral
replic
includ
receptor
bind
membran
fusion
anim
model
develop
may
prove
valuabl
other
evalu
efficaci
therapeut
agent
regim
assess
protect
host
immun
drug
pharmacokinet
crucial
advanc
therapeut
compound
hendra
viru
hev
nipah
viru
niv
close
relat
highli
pathogen
paramyxovirus
emerg
independ
past
year
continu
emerg
new
locat
fli
fox
genu
pteropu
consid
natur
reservoir
virus
demonstr
seroconvers
isol
hevand
nivlik
virus
bat
tissu
secret
addit
extens
serolog
survey
demonstr
presenc
hevor
nivspecif
antibodi
speci
inde
fli
fox
geograph
rang
encompass
locat
hev
niv
found
paramyxovirus
larg
envelop
negativesens
ssrna
virus
includ
wellknown
member
measl
viru
mev
simian
viru
respiratori
syncyti
viru
rsv
divers
viru
famili
variou
member
caus
common
upper
lower
respiratori
tract
infect
less
common
manifest
neurolog
diseas
contrast
niv
hev
distinguish
paramyxovirus
notabl
broad
speci
tropism
high
case
fatal
classifi
new
henipaviru
genu
within
famili
paramyxovirida
hev
appear
sporad
australia
sinc
infect
transmit
hors
human
review
presum
hors
becom
infect
spillov
event
fli
fox
although
viru
isol
fli
fox
outbreak
hors
diseas
present
sever
respiratori
infect
one
two
report
human
mortal
sever
respiratori
diseas
succumb
enceph
month
follow
presum
time
exposur
recent
outbreak
hors
fatal
document
includ
although
human
mortal
occur
one
mildli
ill
seroconvert
human
case
report
niv
first
appear
peninsular
malaysia
singapor
address
correspond
author
australian
anim
health
laboratori
csiro
livestock
industri
portarlington
road
geelong
victoria
australia
tel
fax
email
katharinebossart
csiroau
major
infect
occur
pig
subsequ
transmiss
human
review
pig
infect
larg
subclin
howev
clinic
diseas
observ
manifest
respiratori
encephalit
diseas
low
fatal
ratio
respiratori
case
contrast
human
develop
sever
febril
enceph
high
case
fatal
niv
case
also
exhibit
respiratori
sign
includ
nonproduct
cough
interestingli
relaps
lateonset
enceph
syndrom
signific
fatal
recogn
follow
either
acut
niv
encephalit
episod
nonencephalit
asymptomat
infect
niv
reemerg
numer
time
sinc
twice
bangladesh
west
bengal
india
bangladesh
three
time
bangladesh
recent
nadia
india
signific
observ
bangladesh
indian
niv
outbreak
includ
higher
incid
acut
respiratori
distress
syndrom
conjunct
enceph
epidemiolog
find
consist
persontoperson
transmiss
higher
case
fatal
ratio
furthermor
intermedi
amplif
host
identifi
direct
transmiss
niv
reservoir
host
human
suggest
west
bengal
concurr
ill
anim
bangladesh
common
epidemiolog
link
among
case
drink
fresh
date
palm
sap
gener
believ
date
palm
sap
regularli
contamin
fli
fox
excret
niv
hev
classifi
zoonot
biosafeti
level
virus
infecti
viru
studi
hand
laboratori
worldwid
virus
also
includ
among
variou
pathogen
agent
biodefens
concern
classifi
prioriti
pathogen
categori
c
center
diseas
control
prevent
cdc
nation
institut
allergi
infecti
diseas
niaid
categori
c
agent
includ
high
emerg
pathogen
potenti
caus
morbid
mortal
major
econom
health
impact
henipavirus
particular
could
engin
mass
dissemin
avail
natur
sourc
rel
eas
propag
dissemin
current
specif
antivir
therapi
vaccin
avail
treat
prevent
niv
hev
infect
result
natur
outbreak
laboratori
accid
deliber
misus
two
fatal
case
hev
infect
human
first
present
sever
respiratori
diseas
upon
autopsi
patient
lung
gross
lesion
congest
hemorrhag
edema
associ
chronic
alveol
syncyti
cell
format
second
fatal
case
present
thirteen
month
postexposur
exhibit
leptomening
lymphocyt
plasma
cell
foci
necrosi
variou
part
brain
parenchyma
review
multinucl
endotheli
cell
also
present
viscera
well
brain
first
niv
outbreak
malaysia
enceph
kill
infect
individu
immunoand
histolog
featur
describ
system
endotheli
infect
accompani
vascul
thrombosi
ischaemia
necrosi
chang
especi
note
central
nervou
system
cn
immunohistochem
analys
demonstr
widespread
presenc
niv
antigen
neuron
parenchym
cell
necrot
foci
cn
endotheli
cell
affect
blood
vessel
evid
vascul
endotheli
infect
also
seen
organ
examin
dissemin
endotheli
cell
infect
vascul
thrombosi
cn
parenchym
cell
infect
appear
play
essenti
role
fatal
outcom
human
niv
infect
recent
niv
outbreak
india
bangladesh
similar
clinic
sign
note
howev
higher
incid
acut
respiratori
distress
syndrom
conjunct
enceph
also
describ
paramyxovirus
contain
two
major
membraneanchor
envelop
glycoprotein
requir
infect
recept
host
cell
member
contain
attach
glycoprotein
bind
host
cell
receptor
second
fusion
f
glycoprotein
mediat
phindepend
membran
fusion
viru
host
cell
review
follow
viru
attach
permiss
host
cell
paramyxoviru
mediat
membran
fusion
occur
neutral
ph
result
deliveri
nucleocapsid
cytoplasm
host
cell
paramyxoviru
attach
glycoprotein
possess
hemagglutinin
neuraminidas
activ
hn
bind
sialic
acid
moieti
virion
attach
like
occur
bind
multipl
sialic
acidexpress
protein
cell
surfac
morbilliviru
attach
glycoprotein
h
contain
hemagglutinin
activ
bind
sialic
acid
three
morbillivirus
measl
viru
canin
distemp
viru
rinderpest
viru
employ
cellsurfac
protein
viral
receptor
hev
niv
possess
attach
glycoprotein
g
lack
hemagglutinin
neuraminidas
activ
paramyxovirus
known
util
host
cell
protein
contain
sialic
acid
viral
receptor
specif
ligand
identifi
receptor
util
hev
niv
infect
subsequ
ligand
identifi
altern
receptor
niv
ephrin
molecul
member
famili
receptor
tyrosin
kinas
ligand
highli
conserv
across
vertebr
speci
ephrin
ligand
receptor
play
import
role
regul
tissu
assembl
cell
migrat
critic
brain
function
neuron
network
morphogenesi
ligand
arteryspecif
protein
mediat
blood
vessel
develop
matur
neuron
smooth
muscl
arteri
endotheli
cell
capillari
exhibit
high
level
ligand
express
consist
known
tissu
tropism
hev
niv
vivo
ligand
express
certain
neural
subset
may
play
import
role
hev
niv
infect
cn
paramyxovirus
f
glycoprotein
includ
hev
niv
typic
class
fusion
protein
util
two
intern
heptad
repeat
mediat
membran
merger
review
attach
fusion
critic
step
product
infect
molecul
interfer
either
process
repres
potenti
antivir
agent
fact
extens
character
novel
therapeut
fall
within
categori
discuss
hev
niv
current
classifi
agent
consequ
human
efficaci
studi
test
potenti
therapeut
product
easili
achiev
us
food
drug
administr
fda
implement
anim
efficaci
rule
develop
therapeut
product
circumst
specif
fda
reli
evid
deriv
anim
studi
evalu
product
effect
particular
criteria
met
wellunderstood
mechan
pathogen
agent
underli
mode
action
product
importantli
therapeut
effect
must
also
demonstr
one
anim
speci
criteria
met
human
clinic
trial
could
commenc
like
popul
high
risk
natur
infect
hev
niv
strong
epidemiolog
associ
exist
malaysia
human
niv
infect
close
direct
contact
pig
especi
sick
die
anim
direct
associ
fli
fox
made
epidemiolog
link
note
hev
infect
peopl
hors
die
hev
diseas
neither
hev
diseas
seroconvers
ever
identifi
wildlif
carer
came
close
regular
contact
sick
injur
bat
hors
pig
experiment
infect
hev
niv
respect
neither
repres
practic
option
multipl
experiment
efficaci
studi
larg
anim
hors
difficult
manag
suffici
number
condit
pig
niv
infect
mostli
inconsequenti
clinic
perspect
purpos
review
focu
smaller
anim
model
system
explor
tabl
serolog
evid
niv
infect
rodent
malaysia
howev
attempt
made
infect
mice
experiment
niv
hev
caus
diseas
mice
subcutan
administr
tcid
hev
crameri
g
eaton
bt
unpublish
observ
either
intranas
pfu
niv
intraperiton
pfu
niv
challeng
niv
although
hev
lethal
administ
intracrani
rabbit
suscept
hev
associ
diseas
challeng
subcutan
tcid
hev
guinea
pig
experiment
infect
hev
soon
discoveri
tcid
hev
develop
gener
vascul
affect
lung
kidney
spleen
lymph
node
gastrointestin
tract
skelet
intercost
muscl
howev
spite
vascular
involv
lung
littl
pulmonari
edema
niv
infect
guinea
pig
tcid
niv
clinic
manifest
ruffl
fur
abnorm
less
fear
behavior
gross
patholog
limit
edema
mesenteri
broad
ligament
retroperiton
tissu
signific
microscop
patholog
includ
vascul
fibrinoid
necrosi
endotheli
syncyti
cell
format
myocardium
kidney
lymph
node
spleen
myometrium
retroperiton
tissu
submucos
vessel
bladder
oophor
presenc
hemorrhag
corpora
lutea
also
note
togeth
endometri
degener
necrosi
accompani
multinucl
cell
golden
hamster
anim
model
acut
niv
viru
infect
establish
importantli
enceph
neuron
infect
demonstr
similar
seen
nivinfect
human
ld
valu
hamster
inocul
intraperiton
intranas
rout
pfu
pfu
respect
notabl
brain
sever
affect
organ
term
vascular
parenchym
lesion
neuron
vicin
vasculti
show
numer
cytoplasm
eosinophil
inclus
bodi
viral
antigen
rna
found
extens
throughout
neuron
ultrastructur
analysi
reveal
cytoplasm
inclus
compos
defin
herringbon
nucleocapsid
typic
paramyxovirus
howev
although
hev
niv
clearli
caus
system
diseas
human
niv
detect
serum
sampl
infect
hamster
moreov
patholog
seen
lung
kidney
nivinfect
hamster
differ
seen
hevinfect
hors
nivinfect
human
hev
infect
hamster
report
experiment
hev
infect
cat
perform
find
studi
similar
hors
human
name
gener
vascular
diseas
sever
effect
seen
lung
niv
infect
cat
compar
observ
hev
except
niv
also
extens
inflamm
upper
lower
respiratori
tract
epithelium
associ
presenc
viral
antigen
similar
sever
respiratori
diseas
observ
human
recent
niv
outbreak
bangladesh
cat
succumb
infect
day
follow
parenter
inocul
low
tcid
niv
oronas
administr
tcid
low
passag
plaqu
purifi
hev
niv
bossart
k
bingham
j
middleton
unpublish
data
gross
patholog
common
hev
niv
infect
cat
consist
hydrothorax
dens
purpler
consolid
lung
fluid
accumul
froth
bronchi
review
histolog
cat
infect
niv
develop
necrot
alveol
necrot
foci
develop
within
rang
organ
particularli
kidney
spleen
lymph
node
bladder
ovari
adren
mening
studi
cat
euthan
earli
cours
infect
day
onset
fever
determin
radiotelemetri
measur
bodi
temperatur
indic
alveolar
infect
niv
preced
vascular
infect
suggest
increas
tropism
alveolar
epithelium
compar
vascular
tissu
bingham
j
unpublish
observ
thu
evid
date
indic
cat
repres
anim
model
henipaviru
induc
patholog
close
resembl
lethal
respiratori
diseas
caus
hev
niv
human
experiment
niv
infect
pteropid
bat
attempt
bat
challeng
tcid
niv
remain
clinic
well
throughout
studi
period
febril
respons
record
follow
niv
inocul
via
parenter
rout
challeng
bat
develop
subclin
infect
character
episod
viral
shed
urin
limit
presenc
viru
within
select
viscera
seroconvers
gross
abnorm
identifi
postmortem
examin
anim
variou
time
post
exposur
bat
tissu
neg
upon
immunohistochem
label
niv
antigen
recent
evalu
potenti
ferret
improv
anim
model
niv
infect
ferret
emerg
import
anim
model
sever
major
respiratori
diseas
includ
highli
pathogen
avian
influenza
sever
acut
respiratori
syndrom
sar
also
morbillivirus
closest
rel
hev
niv
signific
similar
exist
ferret
human
lung
physiolog
morpholog
ferret
use
previous
toxicolog
biolog
safeti
assess
studi
confirm
ferret
suscept
niv
infect
diseas
develop
day
follow
oronas
administr
tcid
bossart
k
bingham
j
middleton
unpublish
data
lower
dose
tcid
fail
produc
infect
defin
fever
ill
detect
viru
viral
antigen
viral
genom
histopatholog
lesion
seroconvers
infect
first
manifest
fever
follow
inappet
sever
depress
mild
increas
respiratori
rate
anim
attribut
fever
one
ferret
show
tremor
hindlimb
weak
gross
patholog
includ
subcutan
edema
head
hemorrhag
lymphadenopathi
submandibular
retropharyng
sometim
viscer
lymph
node
numer
diffus
pinpoint
hemorrhag
nodul
scatter
throughout
pulmonari
parenchyma
petechi
hemorrhag
renal
cortex
histopatholog
lesion
includ
focal
necrot
alveol
vascul
degener
glomerular
tuft
focal
necrosi
rang
tissu
includ
lymph
node
spleen
adren
cortex
bladder
ovari
lesion
case
associ
signific
quantiti
viral
antigen
determin
immunohistochem
stain
fig
syncyti
cell
also
frequent
present
lesion
niv
genom
detect
blood
brain
liver
test
adren
kidney
lung
lymph
node
spleen
preliminari
result
encourag
indic
ferret
may
anoth
suitabl
model
human
infect
golden
hamster
cat
ferret
practic
laboratori
anim
model
use
evalu
aspect
diseas
caus
either
hev
niv
amen
therapeut
efficaci
test
larg
domest
anim
particularli
pathogen
hamster
nivassoci
enceph
uniqu
among
small
anim
model
howev
unclear
due
length
clinic
cours
anim
kept
death
occur
natur
studi
anim
euthan
advanc
diseas
onset
tabl
summari
explor
valid
anim
model
critic
futur
explor
therapeut
intervent
strategi
develop
nonhuman
primat
model
hev
niv
infect
yet
attempt
earnest
although
superb
exampl
effect
antivir
drug
target
viral
replic
dna
chaintermin
use
treatment
variou
herp
virus
numer
drug
interfer
replic
human
immunodefici
viru
type
review
vast
major
human
viral
pathogen
vast
shortag
effect
therapi
importantli
date
one
antivir
drug
util
henipaviru
outbreak
ribavirin
first
synthes
perhap
best
known
altern
drug
therapi
exhibit
antivir
activ
varieti
mostli
rna
virus
ribavirin
accept
treatment
sever
viral
infect
includ
rsv
arenavir
hemorrhagicfev
lassa
viru
member
famili
bunyavirida
review
global
avail
broad
antivir
properti
often
employ
treatment
viral
diseas
condit
option
avail
except
support
care
niv
enceph
outbreak
malaysia
evid
ribavirin
exhibit
clinic
benefit
appar
reduct
mortal
littl
evid
seriou
side
effect
thu
ribavirin
appear
one
avail
antivir
option
howev
fatal
approach
recent
niv
outbreak
bangladesh
india
effect
repertoir
antivir
agent
need
hev
niv
transmit
oranas
spread
system
infect
individu
succumb
diseas
within
day
clinic
experiment
data
demonstr
multipl
organ
system
affect
lung
brain
major
site
viru
replic
viremia
document
clinic
experiment
infect
howev
kinet
durat
vari
virus
acut
lateonset
enceph
document
clinic
initi
site
durat
henipaviru
replic
upon
infect
larg
unknown
mainli
due
lack
extens
vivo
experi
consequ
optim
target
time
frame
drug
intervent
known
theoret
therapeut
target
mucosa
reduc
viral
load
lung
intraven
agent
decreas
viral
load
reduc
system
spread
although
target
cn
may
prove
difficult
signific
reduct
viral
load
peripher
may
enabl
host
gener
protect
immun
respons
date
novel
henipaviru
therapeut
agent
identifi
target
interfer
hev
niv
viru
entri
candid
divid
two
categori
use
prevent
diseas
includ
variou
vaccin
use
treatment
postexposur
includ
antibodi
fusion
inhibitor
solubl
receptor
molecul
scope
review
limit
agent
test
use
infecti
hev
niv
vitro
vivo
use
safe
efficaci
vaccin
crucial
prevent
strategi
sever
import
viral
pathogen
human
present
sixteen
fdaapprov
vaccin
routin
use
prevent
infect
virul
human
pathogen
major
compris
liveattenu
viru
prepar
review
although
new
revers
genet
system
develop
niv
unlik
liveattenu
vaccin
approv
viru
includ
hev
niv
success
human
viral
vaccin
induc
neutral
antibodi
crossreact
immunolog
relev
strain
viru
furthermor
neutral
antibodi
key
vaccineinduc
protect
mechan
case
well
known
human
paramyxovirus
mump
mev
paramyxovirus
envelop
glycoprotein
elicit
major
neutral
antibodi
infect
host
inde
henipavirus
demonstr
immun
anim
recombin
niv
hev
f
g
glycoprotein
either
live
vaccinia
viru
vector
purifi
protein
prepar
elicit
potent
crossreact
viru
neutral
humor
respons
hamster
rabbit
respect
first
success
experiment
henipaviru
vaccin
util
recombin
vaccinia
virus
encod
niv
f
g
glycoprotein
studi
vaccin
protect
niv
challeng
golden
hamster
importantli
protect
last
five
month
postchalleng
suggest
protect
potenti
lateonset
diseas
symptom
although
import
proof
principl
recombin
virus
viabl
human
vaccin
candid
due
inher
risk
vaccinia
viru
vaccin
poxviru
vector
emerg
licens
veterinari
vaccin
well
candid
vaccin
human
concern
safeti
wildtyp
vaccinia
viru
address
advent
attenu
poxvirus
modifi
vaccinia
viru
ankara
mva
consid
vaccinia
viru
strain
choic
clinic
investig
although
recombin
mva
express
hev
f
g
gener
neither
test
vaccin
candid
bossart
k
broder
c
unpublish
data
poxviru
vector
shown
attenu
human
avipoxvirus
also
explor
live
vaccin
vector
review
licens
felin
canin
equin
canarypox
virusbas
vaccin
commerci
avail
recent
recombin
canarypox
virusbas
vaccin
encod
niv
f
g
success
protect
pig
niv
challeng
interestingli
neutral
antibodi
cell
mediat
immun
examin
studi
suggest
gcontain
recombin
canarypox
vaccin
could
elicit
protect
humor
type
cellmedi
immun
respons
understand
optim
immun
respons
henipavirus
repres
key
aspect
human
vaccin
develop
importantli
first
report
recombin
canarypox
viru
vaccin
use
pig
repres
signific
progress
toward
veterinari
vaccin
niv
furthermor
evalu
success
independ
anim
model
recombin
niv
fand
gcontain
canarypox
vaccin
could
potenti
use
human
niv
vaccin
candid
recombin
subunit
immunogen
repres
viabl
avenu
vaccin
develop
henipavirus
vaccin
quickli
implement
quit
simpl
administ
risk
infect
recent
recombin
solubl
oligomer
version
g
glycoprotein
hev
niv
sg
gener
potenti
subunit
vaccin
recombin
purifi
sg
prepar
shown
ideal
immunogen
retain
number
import
function
antigen
properti
includ
abil
bind
viru
receptor
block
viru
infect
elicit
robust
polyclon
neutral
antibodi
respons
rabbit
mice
sg
glycoprotein
also
captur
isol
virusspecif
neutral
human
monoclon
antibodi
mab
naiv
recombin
librari
hev
niv
sg
use
subunit
vaccin
cat
niv
challeng
model
anim
protect
diseas
serum
neutral
titer
order
repres
highest
titer
henipavirus
obtain
date
high
neutral
antibodi
titer
absenc
niv
genom
vaccin
anim
follow
challeng
suggest
sg
subunit
vaccin
elicit
steril
immun
unlik
previou
vaccin
strategi
heterotyp
protect
achiev
attach
glycoprotein
hev
protect
challeng
niv
evalu
success
addit
anim
model
subunit
vaccin
may
also
repres
viabl
human
vaccin
candid
potenti
vaccin
discuss
thu
far
summar
tabl
order
henipaviru
vaccin
consid
human
use
need
success
two
anim
model
natur
rout
infect
use
protect
studi
mechan
limit
protect
elicit
highest
standard
use
reagent
product
assur
safeti
success
human
trial
addit
hev
niv
believ
would
ideal
one
vaccin
protect
virus
vaccin
trial
offer
critic
data
toward
goal
refin
reagent
protocol
necessari
firstli
select
adjuv
import
human
use
secondli
correl
vaccin
dose
protect
need
establish
ensur
vaccin
prepar
induc
protect
immun
respons
well
suboptim
level
correl
immun
also
critic
includ
antibodi
subclass
iga
igg
igm
locat
serum
vs
mucu
membran
final
import
determin
role
cellmedi
type
immun
respons
strength
longev
protect
immun
address
concern
new
sg
subunit
vaccin
trial
initi
hev
sg
chosen
antigen
base
previous
establish
gspecif
cross
neutral
titer
elicit
best
crossreact
henipaviru
immun
respons
see
tabl
vari
dose
sg
employ
hope
correl
protect
vaccin
dose
addit
small
cpg
dna
molecul
use
adjuv
sever
reason
recent
studi
demonstr
cpg
molecul
elicit
mucos
system
type
cellmedi
immun
respons
regardless
rout
vaccin
deliveri
equal
import
sever
cpg
molecul
approv
fda
use
human
numer
other
clinic
trial
vaccin
anim
challeng
oronas
low
passag
niv
isol
preliminari
prechalleng
result
summar
tabl
expect
differ
dose
sg
induc
vari
level
serum
neutral
antibodi
titer
significantli
lower
niv
compar
hev
antigenspecif
igg
igm
detect
sera
vaccin
anim
sgspecif
iga
present
serum
one
high
dose
anim
interestingli
hev
sgspecif
iga
detect
mucos
wash
vaccin
anim
postchalleng
titer
protect
diseas
yet
known
howev
data
gener
current
vaccin
trial
valuabl
futur
develop
human
henipaviru
vaccin
neutral
antibodi
elicit
vaccin
highli
effect
purifi
neutral
antibodi
administ
passiv
acut
infect
individu
equal
effici
passiv
antibodi
therapi
routin
use
prophylaxi
sever
import
human
pathogen
includ
hepat
b
varicella
rsv
rabi
viru
advanc
mousehuman
chimer
mab
capabl
human
murin
mab
passiv
antibodi
therapi
becom
even
effici
one
exampl
includ
human
mab
rsv
f
protein
costeffect
highli
sucess
treatment
compar
origin
polyclon
product
passiv
therapi
niv
first
demonstr
use
polyclon
hyper
immun
serum
hamster
hamster
administ
antiniv
f
antiniv
g
polyclon
sera
prior
challeng
anim
surviv
subsequ
niv
challeng
recent
studi
murin
mab
direct
niv
f
g
evalu
lethal
niv
challeng
experi
hamster
mab
administ
prior
shortli
challeng
anim
protect
howev
administ
hour
postchalleng
anim
surviv
togeth
data
demonstr
passiv
transfer
possibl
niv
importantli
develop
postexposur
therapi
human
use
efficaci
treatment
need
increas
beyond
hour
window
murin
mab
may
need
convert
human
molecul
major
advanc
antibodi
technolog
develop
phage
display
platform
combinatori
antibodi
librari
well
domain
chain
shuffl
methodolog
gener
antibodi
new
function
properti
phage
librari
encod
antibodi
form
singlechain
variabl
region
fragment
scfv
fab
fragment
human
phage
display
platform
extens
use
technolog
complement
innov
affin
matur
strategi
obtain
high
affin
reagent
review
new
techniqu
human
phage
display
platform
enabl
technolog
rapid
identif
isol
specif
mab
elimin
timeconsum
process
immun
hybridoma
develop
human
techniqu
neutral
human
mab
reactiv
g
glycoprotein
hev
niv
success
identifi
isol
character
use
recombin
antibodi
techniqu
particular
fab
fragment
signific
neutral
activ
henipavirus
map
receptor
bind
domain
hev
niv
g
subsequ
convert
full
length
human
antibodi
affin
matur
evalu
viru
neutral
assay
human
igg
antibodi
could
complet
neutral
hev
niv
concentr
low
zhu
z
bossart
k
unpublish
data
light
potenc
vitro
mechan
neutral
fact
fulli
human
antibodi
could
provid
valuabl
postexposur
postinfect
therapeut
diseas
caus
hev
niv
human
pharmacolog
assay
current
develop
discuss
consider
advanc
mechanist
model
sever
viral
envelop
glycoprotein
function
drive
membran
fusion
reaction
review
key
compon
mani
fusion
glycoprotein
two
helic
domain
refer
heptad
repeat
hr
involv
format
trimerofhairpin
structur
locat
proxim
amino
n
termin
fusion
peptid
preced
transmembran
domain
near
carboxyl
c
terminu
mani
viral
fusion
glycoprotein
ntermin
form
interior
trimer
coiledcoil
surround
three
antiparallel
helic
form
format
structur
mediat
provid
necessari
energi
drive
viralhost
cell
membran
merger
review
past
decad
target
viral
membran
fusion
process
antivir
drug
develop
receiv
much
attent
primarili
lead
work
review
importantli
envelop
deriv
peptid
enfuvirtid
formerli
clinic
success
enfuvirtid
acid
peptid
correspond
portion
ctermin
domain
subunit
envelop
glycoprotein
peptid
sequenc
deriv
f
glycoprotein
hr
domain
sever
paramyxovirus
includ
hev
niv
shown
potent
inhibitor
fusion
moreov
hev
niv
f
glycoprotein
hr
domain
shown
interact
form
typic
coiledcoil
bundl
henipavirus
second
gener
heptadderiv
peptid
synthes
chemic
modif
either
cterminu
peptid
cap
andor
pegyl
coupl
polyethylen
glycol
peg
protein
specif
chemic
modif
niv
f
heptadderiv
peptid
chosen
especi
pegyl
help
improv
plasma
halflif
thu
enhanc
therapeut
success
pegyl
current
consid
one
success
techniqu
prolong
resid
time
protein
drug
bloodstream
like
predecessor
new
chemic
modifi
heptadderiv
peptid
potent
inhibit
henipaviru
infect
vitro
dosedepend
fashion
plasma
halflif
peptid
recent
evalu
cat
vivo
found
unusu
short
crameri
g
broder
c
unpublish
data
especi
compar
halflif
enfuvirtid
human
pure
carnivor
cat
uniqu
metabol
design
convert
protein
sugar
featur
may
play
role
rapid
clearanc
peptid
bloodstream
reason
peptid
plasma
halflif
current
reevalu
anoth
anim
speci
ferret
pharmacolog
studi
complet
adequ
peptid
plasma
halflif
demonstr
peptid
administ
vivo
examin
efficaci
treatment
ongo
nivmedi
diseas
hope
seen
enfuvirtid
fusion
inhibit
peptid
might
reduc
viral
load
system
spread
vivo
fig
henipaviru
therapeut
agent
evalu
vitro
vivo
addit
use
virusneutr
human
mab
peptid
postexposur
therapeut
modal
hev
niv
infect
solubl
viru
receptor
bind
g
prevent
attach
virion
host
cell
may
also
repres
feasibl
therapeut
strategi
demonstr
solubl
ligand
block
infecti
henipaviru
infect
vitro
recent
demonstr
solubl
ligand
could
block
ligand
mediat
henipaviru
infect
vitro
bossart
k
wang
l
unpublish
data
although
recent
identifi
function
receptor
henipavirus
ligand
cellular
receptor
attract
much
attent
due
role
cancer
biolog
current
solubl
version
molecul
explor
possibl
therapeut
drug
human
cancer
specif
block
receptorligand
interact
inhibit
end
stage
tumor
blood
vessel
format
caus
direct
growth
inhibit
certain
cancer
interestingli
inhibitori
effect
ligand
mediat
henipaviru
infect
natur
receptor
ligand
capabl
block
henipaviru
infect
vitro
bossart
k
wang
l
unpublish
data
potenti
passiv
therapeut
efficaci
solubl
ligand
protein
anim
model
remain
determin
howev
mechan
action
could
view
similar
g
glycoproteinspecif
receptorspecif
antibodi
summari
prevent
postexposur
henipaviru
therapeut
shown
fig
complet
understand
plasma
halflif
toxic
requir
develop
human
use
therapeut
pharmacolog
properti
virusspecif
human
mab
heptadderiv
peptid
current
evalu
vivo
believ
solubl
ligand
studi
commenc
distant
futur
aid
drug
measur
ex
vivo
new
assay
exhibit
extraordinari
sensit
develop
differenti
henipaviru
serolog
neutral
assay
use
bioplex
array
system
recent
describ
assay
use
hev
niv
sgcoupl
fluorescentlylabel
microspher
test
sera
solubl
receptor
phycoerythrinlabel
detect
molecul
bind
result
report
median
fluoresc
intens
although
develop
detect
host
antibodi
interf
receptor
bind
assay
easili
adapt
measur
therapeut
bound
attach
glycoprotein
hev
niv
sg
coupledmicrospher
use
detect
ligand
gspecif
human
mab
approxim
sensit
ngml
pgml
respect
bossart
k
unpublish
data
clearli
assay
prove
valuabl
detect
solubl
ligand
sera
alreadi
use
measur
gspecif
human
mab
sera
plasma
halflif
experi
final
anoth
microspherebas
assay
capabl
measur
fspecif
heptadderiv
peptid
sera
develop
assay
microspher
coat
heptadderiv
peptid
detect
use
peptidespecif
polyclon
antibodi
antirabbitphycoerythrin
molecul
result
report
median
fluoresc
intens
test
sera
ad
free
peptid
compet
antibodi
bind
thu
decreas
fluoresc
signal
detect
similar
microspher
assay
new
peptid
assay
approxim
sensit
ngml
exampl
standard
curv
assay
shown
fig
develop
assay
enabl
accur
measur
potenti
therapeut
agent
ex
vivo
set
stage
evalu
efficaci
henipaviru
anim
challeng
model
increas
understand
henipaviru
pathogenesi
lead
develop
suitabl
anim
model
diseas
potenti
therapeut
success
vaccin
candid
trial
one
anim
model
still
need
evalu
independ
anim
model
addit
discuss
provid
import
proof
concept
data
understand
protect
mechan
refin
reagent
critic
vaccin
candid
progress
postexposur
therapeut
agent
test
vitro
requir
vivo
halflif
studi
diseas
prevent
efficaci
studi
least
two
anim
model
complex
studi
includ
optim
drug
deliveri
vivo
sitespecif
target
postexposur
antivir
although
mani
avenu
henipaviru
therapeut
research
success
like
take
least
five
ten
year
therapeut
agent
undergo
necessari
test
gain
fda
approv
use
routin
outbreak
understand
molecular
biolog
hev
niv
expand
rapidli
recent
year
although
review
limit
agent
test
infecti
viru
numer
vitro
cell
cultur
system
develop
examin
variou
henipaviru
genespecif
function
consequ
proteinbas
mechan
attach
fusion
f
cleavag
interferon
interfer
viru
particl
format
elicit
importantli
process
repres
target
new
antivir
drug
develop
high
throughput
screen
specif
inhibit
assay
well
underway
construct
niv
revers
genet
system
although
unlik
use
vaccin
trial
significantli
aid
gene
knock
studi
use
infecti
clone
new
therapeut
target
like
identifi
new
therapeut
gene
silenc
techniqu
small
interf
rna
molecul
also
develop
niv
character
gene
current
target
howev
new
genom
region
identifi
use
revers
genet
also
repres
potenti
sequenc
target
vast
expans
henipaviru
molecular
biolog
underpin
new
drug
discoveri
howev
viru
neutral
assay
drug
character
vivo
efficaci
studi
still
repres
challeng
phase
drug
develop
hev
niv
especi
restrict
